Hyperparathyroidism
📧 Sign up to get email alerts when something new happens for Hyperparathyroidism.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy [NA]
A completed clinical trial evaluated the impact of near-infrared auto-fluorescence (NIRAF) detection for identifying parathyroid glands duri…
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD [Phase 2]
Phase 2 clinical trial evaluating whether increasing dialysate calcium alters T50 in people with secondary hyperparathyroidism and end-stage…
-
CLINICAL_TRIALS trial_result · 2024-04-29Clinical Trial Update: Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT [Phase 4]
Phase 4 trial evaluating the efficacy and safety of cinacalcet on calcium, phosphorus, and iPTH levels in patients with secondary hyperparat…
-
FDA approval · 2024-01-19FDA Approved: RAYALDEE — Supplemental Application (OPKO Pharmaceuticals LLC)
FDA approved a supplemental application for RAYALDEE (calcifediol) from OPKO Pharmaceuticals LLC under NDA 208010, authorizing changes to th…
-
FDA approval · 2023-12-08FDA Approved: CINACALCET — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for Accord Healthcare’s generic cinacalcet product. The approval confirms continued market availabil…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol [Phase 4]
Phase 4 trial comparing calcitriol versus paricalcitol for management of mineral and bone disorders in hemodialysis, terminated with posted …
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention [Phase 3]
Phase 3 trial comparing Tc99m-sestaMIBI SPECT/CT vs F18-choline PET/CT for preoperative localization in primary hyperparathyroidism complete…
-
FDA approval · 2023-07-28FDA Approved: CINACALCET — Supplemental Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's supplemental application for Cinacalcet, granting approval of a generic cinacalcet product.
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: A Study of SHR6508 in Secondary Hyperparathyroidism [Phase 2]
Phase 2 clinical trial update for SHR6508 in secondary hyperparathyroidism.
-
FDA approval · 2023-06-15FDA Approved: DOXERCALCIFEROL — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved an original application for doxercalciferol as a generic drug, expanding access to this vitamin D analog.
-
CLINICAL_TRIALS trial_result · 2023-05-03Clinical Trial Update: Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism [Phase 2, Phase 3]
A Phase 2/Phase 3 trial evaluating alternative medical therapies for primary hyperparathyroidism has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). [Phase 3]
Phase 3 trial evaluating teriparatide injections to prevent hypocalcemia after parathyroidectomy in dialysis patients has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: Osteoporosis in Primary Hyperparathyroidism [Phase 4]
Phase 4 clinical trial update investigating osteoporosis in the context of primary hyperparathyroidism.
-
CLINICAL_TRIALS trial_result · 2022-11-02Clinical Trial Update: Denosumab in Primary Hyperparathyroidism [Phase 4]
Phase 4 trial update for denosumab in primary hyperparathyroidism has been terminated with results posted.
-
FDA label_change · 2022-10-20FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for ZEMPLAR (paricalcitol) filed by AbbVie, resulting in changes to its labeling.
-
CLINICAL_TRIALS trial_result · 2022-06-07Clinical Trial Update: Studies of Elevated Parathyroid Activity [Phase 2]
Phase 2 clinical trial updates on studies of elevated parathyroid activity completed; results posted.
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia [Phase 3]
Phase 3 trial of KHK7580 in subjects with secondary hyperparathyroidism in Asia has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism [Phase 3]
Phase 3 clinical trial assessing paricalcitol for secondary hyperparathyroidism in chronic kidney disease; status not specified.
-
FDA approval · 2022-01-24FDA Approved: DOXERCALCIFEROL — Original Application (Eugia US LLC)
FDA approved an original application for doxercalciferol (generic) by Eugia US LLC.
-
FDA approval · 2021-12-02FDA Approved: CINACALCET HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal Pharmaceuticals' cinacalcet hydrochloride generic under an Original Application (ANDA), enabling a generic version of ci…
-
CLINICAL_TRIALS trial_result · 2021-10-12Clinical Trial Update: Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients [Phase 4]
A Phase 4 trial comparing cinacalcet to parathyroidectomy in peritoneal dialysis patients with secondary hyperparathyroidism has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism [Phase 3]
Phase 3 study of KHK7580 for hypercalcemia in parathyroid carcinoma or primary hyperparathyroidism completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. [Phase 3]
Phase 3 trial evaluating denosumab and cinacalcet for primary hyperparathyroidism; study completed with posted results in 2021.
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) [Phase 3]
Phase 3 head-to-head trial comparing etelcalcetide with cinacalcet in Asian hemodialysis patients with secondary hyperparathyroidism has com…
-
FDA approval · 2021-03-02FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for ZEMPLAR (paricalcitol) submitted by AbbVie Inc.